



CHAPTER V

REFERENCES

- Brekelmans C. T. M, C. Seynaeve, M. Menke-Pluymers, H. T. Bruggenwirth, M. M. A. Tilanus-Linthorst, C. C. M. Bartels, M. Kriege, A. N. van Geel, C. M. G. Crepin, J. C. Blom, H. Meijers-Heijboer and J. G. M. Klijn. Survival and prognostic factors in BRCA1-associated breast cancer
- Claus EB, Schildkraut JM, Thompson WD, et al: The genetic attributable risk of breast and ovarian cancer. 2000.
- Ford D, Easton DF, Stratton M, et al: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62, 1998
- Gaffney DK, Brohet RM, Lewis CM, et al: Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations. Radiother Oncol 47: 129-136, 1998
- Joyce A. O'Shaughnessy, Molecular Signatures Predict Outcomes of Breast Cancer, 2006
- King MC: Genetic analysis of cancer in families. Cancer Surv 9: 417-435, 1990
- Kasper, Braunwald, Fauci, Hauser, Longo, Jameson, Harrison's Principle of Internal Medicine, 16<sup>th</sup> edition, 2005.
- Marcus JN, Watson P, Page DL, et al: Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer, 1996
- Mark E Robson, Pierre O Chappuis, Jaya Satagopan, Nora Wang, Jeff Boyd, John R Goffin, Clifford Hudis, David Roberge, Larry Norton, Louis R Bégin, Kenneth Offit and William D Foulkes. A combined analysis of outcome following breast cancer : differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment, 2004.
- Osin P, Gusterson BA, Philp E, et al. Predicted anti-oestrogen resistance in BRCA-associated familial breast cancers. Eur J Cancer. 1998
- Osin P, Crook T, Powles T, Peto J, Gusterson B. Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers. Lancet. 1998
- Pinchas P Osin, Sunil R Lakhani, The pathology of familial breast cancer: Immunohistochemistry and molecular analysis, 1999



## Survival of Hereditary Susceptible Breast Cancer Patients

Nur Farhana bt Ahmad Murad, Dr. Teguh Aryandono, SpB(K), Onk.; dr. Endro Basuki S, SpB.; MKes. 50  
Universitas Gadjah Mada, 2007 | Diunduh dari <http://etd.repository.ugm.ac.id/>

UNIVERSITAS  
GADJAH MADA

Sigurdsson H, Agnarsson BA, Jonasson JG: Worse survival among breast cancer patients in families carrying the BRCA2 susceptibility gene, 1996.

Struewing JP, Hartge P, Wacholder S, et al: Cancer risk with 185delAG and 5382insC mutations of BRCA1 and the 6174delT mutation of BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401-1408, 1997

Thomas C Putti, Dalia M Abd El-Rehim, Emad A Rakha, Claire E Paish, Andrew HS Lee, Sarah E Pinder and Ian O Ellis, Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis, 2004

Verhoog L. C, E. M. J. J. Berns, C. T. M. Brekelmans, C. Seynaeve, E. J. Meijers-Heijboer, J. G. M. Klijn, Prognostic Significance of Germline BRCA2 Mutations in Hereditary Breast Cancer Patients, 2000

Vinay Kumar MD, Ramzi S. Cotran MD, Stanley L. Robbins MD, Basic Pathology 7<sup>th</sup> edition. Saunders 2004

Wobbes T, van de Wiel MP, van der Sluis RF, et al: The effect of familiarity on clinical presentation and survival in mammary carcinoma. Eur J Sur Oncol 13:119-121, 1987

Yoo KY, Tajima K, Miura S S. A hospital-based case-control study of breast-cancer risk factors by estrogen and progesterone receptor status. Cancer, Causes & Control. 1993